TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02009787
Drug: placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU placebo tablets were taken daily for 6 months
Study: NCT04380142
Drug: Placebo for Levodopa/Carbidopa (LD/CD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT04380142
Drug: Levodopa/Carbidopa (LD/CD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral encapsulated tablet
Study: NCT04380142
Drug: Placebo for ABBV-951
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for continuous subcutaneous infusion (CSCI)
Study: NCT00654732
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03880357
Drug: Taclonex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
Study: NCT03880357
Drug: Placebo topical suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
Study: NCT01481610
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
Study: NCT01481610
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
Study: NCT03577457
Drug: ATD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
Study: NCT03577457
Drug: intranasal placebo treatment (placebo-control for oxytocin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration of placebo nasal spray
Study: NCT03577457
Drug: oral placebo treatment (placebo-control for ATD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of a tryptophan-balanced mixture (78.2g)
Study: NCT04426474
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04426474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04269954
Drug: Batroxobin combined with low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of Batroxobin combined with low molecular weight heparin
Study: NCT05586750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
Study: NCT00811837
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT01939145
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
Study: NCT02020161
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000621
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02740985
Drug: AZD4635
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
Study: NCT04736355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, for 24 weeks
Study: NCT03713801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks
Study: NCT00867607
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. 21 days
Study: NCT00586157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
Study: NCT00145730
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01318681
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a placebo nasal spray and placebo capsule are available for double dummy treatment
Study: NCT02573064
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00693758
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion of adenosine (140microgr./min/kg)
Study: NCT01846026
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02229617
Drug: Subcutaneous testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01270152
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
Study: NCT00470522
Drug: Methotrexate and folic acid
Normalized name: ferrous fumarate and folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02150161
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02972645
Drug: LY3305677
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02972645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00664222
Drug: spironolactone + furosemide
Normalized name: furosemide / spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
Study: NCT00030264
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
Study: NCT02191163
Drug: Antistax®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02191163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02119273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT00892580
Drug: STX209
Approvals — FDA: no, EMA: no, PMDA: no
Description: collection of serum for DNA to elucidate a potential biomarker for patients with ASD
Study: NCT00227110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is given to match pioglitazone.
Study: NCT01164826
Drug: Nabumetone
Normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
Study: NCT02232360
Drug: Rosuvastatin and fenofibrate
Normalized name: rosuvastatin and fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
Study: NCT02232360
Drug: Rosuvastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10mg per day
Study: NCT02348021
Drug: Dual Anti Platelet Therapy
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive Dual Anti Platelet Therapy for one month
Study: NCT03984825
Drug: GSK3640254
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.
Study: NCT00444314
Drug: Panzem® NCD
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCD suspension, 1500 mg TID daily for 6 week cycles
Study: NCT01006733
Drug: Target INR 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
Study: NCT03640884
Drug: Xueshuantong-Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
Study: NCT01515371
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
Study: NCT01841996
Drug: ME1111 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day for 28 days
Study: NCT01841996
Drug: Vehicle Solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day for 28 days
Study: NCT01943760
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03483948
Drug: HMPL-523
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-523 tablet
Study: NCT03008187
Drug: SEL24/MEN1703
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
Study: NCT02441218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
Study: NCT00452829
Drug: Folic Acid and inositol
Normalized name: folic acid / inositol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic Acid and inositol
Study: NCT00452829
Drug: Folic acid and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid and placebo
Study: NCT00739037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00739037
Drug: PAZ-417
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00806585
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00806585
Drug: Comparator: HCTZ
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01959685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, single dose
Study: NCT00474903
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01103414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily for 84 days
Study: NCT01170663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
Study: NCT01927913
Drug: SPD602
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32, 50 or 75 mg/kg/day BID, capsule
Study: NCT00427037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo pill orally by mouth
Study: NCT03229538
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline pre-operative and intra-operative
Study: NCT02621892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02073474
Drug: Sativex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
Study: NCT03121521
Drug: Melatonin 10 mg
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: melatonin 10mg daily p.o.
Study: NCT03121521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10mg daily p.o.
Study: NCT01358162
Drug: SQ109
Normalized name: SQ109
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
Study: NCT00060476
Drug: rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00060476
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02045602
Drug: Abraxane®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg/m2 intravenous administration
Study: NCT00361712
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with parturients with cervical dilatation and painful labor (VAS \>5)
Study: NCT01596270
Drug: SAR245409
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT04581395
Drug: succinylcholine 1 minute after rocuronium pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 1 min +/- 10 sec after pretreatment
Study: NCT04581395
Drug: succinylcholine 2 minutes following rocuronium pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 2 min +/- 10 sec after pretreatment.
Study: NCT03083184
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
Study: NCT04361279
Drug: SIBP-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection，100mg/10ml
Study: NCT00679263
Drug: MN-221
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
Study: NCT00679263
Drug: MN-221
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
Study: NCT00679263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion with dosing volume equivalent to active treatment.
Study: NCT04544280
Drug: Xeomin Injectable Product
Normalized name: Xeomin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT00185341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01813084
Drug: RV1729 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of single escalating doses
Study: NCT01813084
Drug: RV1729 matching placebo single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of single escalating doses
Study: NCT01813084
Drug: RV1729: 14 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat escalating doses
Study: NCT01813084
Drug: RV1729 matching placebo: 14 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat escalating doses
Study: NCT03279952
Drug: CNS Stimulant
Normalized name: CNS STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
Study: NCT03817580
Drug: Project X 26ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Study: NCT03817580
Drug: Project X 5.1ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Study: NCT00538850
Drug: Fentanyl sublingual spray
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
Study: NCT00538850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to fentanyl sublingual spray.
Study: NCT02645799
Drug: LABR-312
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
Study: NCT03849261
Drug: D635
Normalized name: FILTER,SUCTION DEVILBISS #7305D635
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug
Study: NCT02106832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
Study: NCT02106832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
Study: NCT01416350
Drug: Azithromycin - 250 mg
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part A - A single azithromycin dose of 250 mg.
Study: NCT01416350
Drug: Azithromycin - 1000 mg
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part A - A single azithromycin dose of 1000 mg.
Study: NCT01416350
Drug: Azithromycin - 250 mg every other day for 3 weeks
Normalized name: azithromycin 250 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
Study: NCT01139151
Drug: 3 Day Thiarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 70 mg/m\^2 IV over 1 hour (±15 minutes) daily x 3
Study: NCT01139151
Drug: 5 Day Thiarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
Study: NCT04490681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group
Study: NCT04342247
Drug: external testosteron
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: external testosteron
Study: NCT02027792
Drug: Diclofenac Gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04106778
Drug: DMT310
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Powder
Study: NCT04106778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Topical Powder
Study: NCT03290027
Drug: DFD-03
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFD-03 Lotion
Study: NCT00874601
Drug: Diovan® (valsartan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded.
Study: NCT00963872
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg intravenously (IV) over 2 hours on Day -6.
Study: NCT01696643
Drug: CB-5945
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01696643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no